Clinical Application of Nimotuzumab in Locally Advanced Head and Neck Malignancies

Liu Yanhui; Jiang Ping; Zhao Xin

doi:10.3969/j.issn.1004-5775.2026.03.019

Abstract：Objective:There has been expert consensus that nimotuzumab has a good therapeutic effect in the treatment of locally advanced head and neck tumors.It aims to demonstrate the clinical efficacy and adverse reactions of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced head and neck squamous cell carcinoma patients.Methods:Thirty patients with locally advanced head and neck squamous cell carcinoma admitted to our hospital from September 2022 to June 22,2024 were randomly divided into two groups,15 cases in each group.The control group was treated with concurrent chemoradiotherapy,and the observation group was treated with nimotuzumab on the basis of the control group.The short-term efficacy and adverse reactions of the two groups were compared.Results:In the control group,0 cases had CR,6 cases had PR,3 cases had SD,and 5 cases had PD.The ORR was 60%(9/15).In the observation group,6 cases had complete response(CR),7 cases had partial response(PR),2 cases were stable(SD),and 0 cases were progressive(PD).The objective response rate(ORR)was 86%(13/15).The recent therapeutic effect of the patients in the observation froup was better than that in the control group,with statistically differences(P＜0.05).The main adverse reactions in the two groups were radiation mucositis,loss of appetite,general fatigue and bone marrow suppression.Conclusion:Nimotuzumab combined with concurrent chemoradiotherapy has better efficacy and safety than chemoradiotherapy alone.